It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (NYSE: ABBV). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to ...

AbbVie is poised to grow this year for the first time since Humira's U.S. patent expired. The dividend yields a generous 3.7% and features decades of consistent growth. While tariffs, politics ...

In the latest market close, AbbVie (ABBV) reached $170.16, with a -1.64% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 2.36% for the day.

You can create a release to package software, along with release notes and links to binary files, for other people to use. Learn more about releases in our docs.

Financial giants have made a conspicuous bearish move on AbbVie. Our analysis of options history for AbbVie ABBV revealed 20 unusual trades. Delving into the details, we found 45% of traders were ...

AbbVie finds itself under the microscope as investors hunt for stocks with long-term staying power, and it’s bringing its A-game. AbbVie’s forecast includes high single-digit annual revenue growth ...

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

AbbVie has had a dramatic year, juggling a Humira hangover, political landmines, and a costly failed drug trial. Despite a major flop on a $9 billion acquisition, AbbVie’s new immunology duo, Skyrizi ...